The Performance of Nesfatin-1 in Distinguishing Irritable Bowel Syndrome Presenting Predominantly with Diarrhea from Celiac Disease

Basit Öğe Kaydı
dc.contributor.authorKaratay, Eylem
dc.contributor.authorGül-Utku, Özlem
dc.contributor.authorAksoy, Neval
dc.date.accessioned2021-01-14T18:11:02Z
dc.date.available2021-01-14T18:11:02Z
dc.date.issued2020
dc.departmentKKÜ
dc.description.abstractBackground: We hypothesized that nesfatin-1, an anti-inflammatory peptide, could be used as a non-invasive diagnostic tool in the identification of celiac disease (CD) and irritable bowel syndrome presenting predominantly with diarrhea (IBS-D). Methods: Thirty-five patients with IBS-D who met the Rome III criteria, 28 patients with celiac disease who met the diagnostic criteria of the Marsh-Oberhuber classification, and 30 age- and gender-matched healthy controls were included in this cross-sectional study. All subjects responded to the IBS Severity Scoring System (IBS-SSS) questionnaire that was used to determine pain severity, pain frequency, bloating, dissatisfaction with bowel habits, and life interference. Results: Nesfatin-1 levels were significantly higher in the CD group compared to the IBS-D group and healthy controls. Nesfatin-1 was also higher in the IBS-D group compared to controls. Nesfatin-1 levels were correlated with IBS-SSS (r = 0.884, p < 0.001), severity of abdominal pain and discomfort (r = 0.644, p < 0.001), and C-reactive protein concentrations (r = 0.303, p = 0.004). ROC curve analysis demonstrated that a cutoff value of > 98.1 pg/mL for nesfatin-1 could discriminate subjects with CD from those with IBS-D and also healthy controls with a sensitivity of 82% and a specificity of 80%. Conclusions: The results of this study show that subjects with CD have higher nesfatin-1 levels compared to those with IBS-D or to the healthy controls. Moreover, nesfatin-1 can discriminate subjects with CD from those with IBS-D and also healthy controls, with high sensitivity and specificity. Further studies with histopathological evaluation are required to clearly address the role of nesfatin-1 in the diagnosis of CD.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.7754/Clin.Lab.2020.191215
dc.identifier.endpage455en_US
dc.identifier.issn1433-6510
dc.identifier.issue3en_US
dc.identifier.pmid32162872
dc.identifier.scopus2-s2.0-85081917157
dc.identifier.scopusqualityQ3
dc.identifier.startpage449en_US
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2020.191215
dc.identifier.urihttps://hdl.handle.net/20.500.12587/12861
dc.identifier.volume66en_US
dc.identifier.wosWOS:000545455100028
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCLIN LAB PUBLen_US
dc.relation.ispartofCLINICAL LABORATORY
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectirritable bowel syndromeen_US
dc.subjectceliac diseaseen_US
dc.subjectnesfatin-1en_US
dc.subjectinflammationen_US
dc.titleThe Performance of Nesfatin-1 in Distinguishing Irritable Bowel Syndrome Presenting Predominantly with Diarrhea from Celiac Diseaseen_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu